SAB Biotherapeutics (SABS) Common Equity (2020 - 2026)

SAB Biotherapeutics has reported Common Equity for 7 years, with the latest figure at $227.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 961.54% year-over-year to $227.2 million; the trailing twelve-month figure through Mar 2026 stood at $227.2 million (up 961.54% YoY), and the FY2025 full-year result was $151.5 million, up 483.35% from the prior year.
• Common Equity for Q1 2026 stood at $227.2 million, up from $151.5 million in the prior quarter.
• The five-year high for Common Equity was $227.2 million in Q1 2026, with the low at $12.0 million in Q2 2025.
• Historically, Common Equity has averaged $58.6 million across 5 years, with a median of $36.9 million in 2024.
• Annual changes were most pronounced in 2025 — Common Equity sank 73.95% — and 2026, when it surged 961.54%.
• SAB Biotherapeutics' Common Equity stood at $31.1 million in 2022, then jumped by 84.49% to $57.3 million in 2023, then sank by 54.68% to $26.0 million in 2024, then surged by 483.35% to $151.5 million in 2025, then surged by 50.0% to $227.2 million in 2026.
• The last three Common Equity figures came in at $227.2 million (Q1 2026), $151.5 million (Q4 2025), and $165.1 million (Q3 2025), per Business Quant data.